Rachael Natrajan - Concepedia

Author

Rachael Natrajan

Also Known As

Natrajan, Rachael, R Natrajan, R. Natrajan, Rachael C Natrajan, Rachael C. Natrajan, Rachael Natrajan, Rachael C. Natrajan, Rachel Natrajan

380

Publications

15.3K

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research Breast Cancer Now Breast Cancer Research Foundation Cancer Research UK Institut Curie

About

Rachael Natrajan is an author at Institute of Cancer Research specializing in medicine, breast cancer, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	35	6.9K
2	Health Sciences	6	6	441
3	Engineering	5	5	907
4	Natural Sciences	5	5	1.3K
5	Biochemistry	1	1	50

Rachael Natrajan

107

Publications

14.2K

Citations

H-Index

Page 1

	Year	Citations
Resistance to therapy caused by intragenic deletion in BRCA2 Stacey L. Edwards, Rachel Brough, Christopher J. Lord, Nature Intragenic DeletionOncogenic AgentPathologyCancer GeneticsMedicine	2008	979
Complex landscapes of somatic rearrangement in human breast cancer genomes Philip J. Stephens, David J. McBride, Meng‐Lay Lin, Nature ChromatinComplex LandscapesSomatic VariantTumor HeterogeneityNatural Sciences	2009	838
BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells Gemma Molyneux, Felipe C. Geyer, Fiona‐Ann Magnay, Cell stem cell Lineage PlasticityBreast OncologyDevelopmental BiologyMedicineBreast Cancer	2010	800
<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer Nicholas C. Turner, Alex Pearson, Rachel Sharpe, Cancer Research Endocrine OncologyBreast OncologyEndocrine-related CancerMedicineCancer Cell Biology	2010	712
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets Nicholas C. Turner, Maryou B. Lambros, Hugo M. Horlings, Oncogene Breast OncologyFunctional GenomicsPotential Therapeutic TargetsEngineeringMedicine	2010	405
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma Munir R. Tanas, Andrea Sboner, André M. Oliveira, Science Translational Medicine	2011	395
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation Felipe C. Geyer, Magali Lacroix‐Triki, Kay Savage, Modern Pathology Transcriptional RegulationRadiation OncologyOncologyBreast OncologyMedicine	2010	371
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity Ilirjana Bajrami, Jessica Frankum, Asha Konde, Cancer Research EngineeringMolecular BiologyPathologySmall-molecule InhibitorsGene Characterization	2013	361
Breast cancer molecular profiling with single sample predictors: a retrospective analysis Britta Weigelt, Alan Mackay, Roger A’Hern, The Lancet Oncology	2010	359
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer Dan R. Robinson, Shanker Kalyana‐Sundaram, Yi Mi Wu, Nature Medicine Recurrent RearrangementsBreast OncologyReceptor Tyrosine KinaseBreast CancerCancer Genetics	2011	341

Page 1